Researchers at 12 hospitals in Canada and Denmark prospectively analyzed data from 41 women with IBD who received vedolizumab (VDZ; Entyvio, Millennium Pharmaceuticals) during pregnancy.
According to the authors, 16% of women miscarried, all during the first trimester. Among the live births, one newborn had a low Apgar score at five minutes, two infants were born preterm, and three babies were small for their gestational age. No neonates experienced congenital malformations.